ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.

Marie-Agnès Doucey,Blandine Pouleau,Carole Estoppey,Cian Stutz,Amélie Croset,Amelie Laurendon,Thierry Monney,Mégane Pluess,Christelle Ries Fecourt,Julie Macoin,Riccardo Turrini,Perrine Suere,M. Lamine Mbow,Emilie Nallet,Adam Drake,Mario Perro,Stanislas Blein

ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.

2021

Marie-Agnès Doucey
Blandine Pouleau
Carole Estoppey
Cian Stutz
Amélie Croset
Amelie Laurendon
Thierry Monney
Mégane Pluess
Christelle Ries Fecourt
Julie Macoin
Riccardo Turrini
Perrine Suere
M. Lamine Mbow
Emilie Nallet
Adam Drake
Mario Perro
Stanislas Blein

8044Background: ISB 1342 is a bispecific antibody heterodimer based on the Ichnos proprietary Bispecific Engagement by Antibodies based on T cell receptor (BEAT) platform. ISB 1342 is a first-in-cl...

Keywords:

Medicine
CD38
relapsed refractory
Cancer research
bispecific antibody
Antibody
T-cell receptor
T cell
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations